X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

"If Washington isn’t careful, we might leave innovation behind"

By Robert Zirkelbach  |    June 24, 2019
“Trying to make medications more affordable is important, but if Washington isn’t careful, we might leave innovation behind.” This is the message we heard from Amy, a Voters for Cures advocate from...   Read More

New report shows over 500 medicines in development for neurological disorders

By Andrew Powaleny  |    April 18, 2018
Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the U.S. population....   Read More

ICYMI: Why 2017 medicine approvals matter

By Andrew Powaleny  |    January 12, 2018
This week, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) released its 2017 New Drug Therapy Approvals report. Last year marked an extraordinary...   Read More

Disease modifying therapies for the management of multiple sclerosis save money and improve patient outcomes

By Samantha Dougherty  |    October 24, 2017
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a recent study comparing the effectiveness of oral and injectable...   Read More

How do multiple sclerosis patients define value?

By Lauren Neves  |    February 24, 2017
There are crucial conversations occurring in the health care system about how value is defined. To explore how multiple sclerosis (MS) patients, providers and payers view value, Real Endpoints...   Read More

Video: Translating science into new medicines

By Andrew Powaleny  |    December 12, 2016
Researchers and scientists at America’s biopharmaceutical companies and around the globe work every day to translate science into new treatments and cures to allow patients to live longer, healthier...   Read More

ICER glosses over significant progress in MS treatment

By Holly Campbell  |    November 30, 2016
Multiple sclerosis (MS) is a devastating chronic autoimmune disease that can affect a person’s brain, spinal cord and optic nerves, causing problems with vision, balance, muscle control and other...   Read More

Dr. George Scangos: Not just science for science’s sake

By Andrew Powaleny  |    August 10, 2016
America’s biopharmaceutical researchers are working tirelessly to develop new and innovative medicines for patients. For those diseases that have no treatment options, the opportunity to improve...   Read More

Science of Hope: Incorporating the patient perspective

By Andrew Powaleny  |    June 29, 2016
For many of America’s biopharmaceutical researchers and scientists, seeing the positive effects of their work on the lives of patients is what encourages them to keep striving. Dr. Al Sandrock, chief...   Read More

Burden on patients: Access to medicines in health insurance exchange plans

By Allyson Funk  |    June 23, 2016
Access to prescription medicines is critical to help patients manage their chronic conditions and maximize quality of life. Unfortunately, even with insurance coverage, many patients still struggle...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates